# Comparing Efficacy and Safety Between Pertuzumab® and Perjeta® in Neoadjuvant Treatment of HER2+ Breast Cancer

> **NCT04957212** · PHASE3 · COMPLETED · sponsor: **Cinnagen** · enrollment: 214 (actual)

## Conditions studied

- HER2-positive Breast Cancer

## Interventions

- **DRUG:** Trastuzumab
- **DRUG:** Pertuzumab
- **DRUG:** Carboplatin
- **DRUG:** Docetaxel

## Key facts

- **NCT ID:** NCT04957212
- **Lead sponsor:** Cinnagen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-08-11
- **Primary completion:** 2020-05-27
- **Final completion:** 2020-05-27
- **Target enrollment:** 214 (ACTUAL)
- **Last updated:** 2024-07-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04957212

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04957212, "Comparing Efficacy and Safety Between Pertuzumab® and Perjeta® in Neoadjuvant Treatment of HER2+ Breast Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04957212. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*